查看文章

Objectives

In the absence of head-to-head trials, matching-adjusted indirect comparisons (MAIC) was conducted to compare efficacy and safety of filgotinib vs. tofacitinib in patients with moderately to severely active ulcerative colitis (UC) after adjusting for cross-trial differences.

Methods

Individual patient data (IPD) from SELECTION for filgotinib 200mg and published aggregate data for tofacitinib from OCTAVE 1&2 (induction) and OCTAVE SUSTAIN (maintenance) were used. SELECTION IPD were weighted to match average baseline characteristics in OCTAVE for the active treatment and placebo arms, including sex, age, weight, smoking status, total Mayo score, UC duration, history of biologic failure, and concomitant corticosteroid use. Efficacy outcomes were compared separately for biologic-naïve and biologic-experienced subgroups in both induction and maintenance phases. Safety outcomes were compared …